News of the WeekImmunology

Interleukin-13's Key Role in Asthma Shown

+ See all authors and affiliations

Science  18 Dec 1998:
Vol. 282, Issue 5397, pp. 2168
DOI: 10.1126/science.282.5397.2168a

As any sufferer can tell you, an asthma attack is nothing to sneeze at. In a dramatic—and dangerous—overreaction by the immune system, the lungs pump out mucus and inflammatory molecules, clogging and swelling constricted airways; in severe cases, all airflow is cut off, and the attack can be fatal. Now, on pages 2258 and 2261, two independent teams present evidence that an immune system messenger called interleukin-13 (IL-13) may be a key culprit in such attacks. The results come from mouse studies, but if they hold up in humans, they suggest two promising targets for antiasthma therapies.

Although IL-13 was known to play a role in asthma, it was typically overshadowed by its better-known sibling molecule, interleukin-4, another member of the cytokines—a group of messenger molecules that help coordinate the body's immune responses. The new work suggests, however, that IL-13 was unjustly overlooked. “[The work] alerts people who have dismissed IL-13 to its importance, along with IL-4, in asthma,” says immunologist Charles Maliszewski of Immunex Corp. in Seattle.

Until now it was difficult to separate the roles of IL-13 and IL-4, because they seemed to have very similar effects and dock on very similar receptor complexes at the surface of immune system cells. But a new molecule that selectively mops up IL-13 from airways has allowed the two teams of scientists to clarify the roles of these twin messengers—and show that IL-13 is a key player in its own right.

The new molecule, developed by immunologist Debra Donaldson of Genetics Institute in Cambridge, Massachusetts, is a soluble version of a recently cloned piece of a cell surface receptor that is specific to IL-13. The molecule binds to the cytokine, preventing it from attaching to its receptors.

Immunologist Marsha Wills-Karp of Johns Hopkins University and her colleagues gave the IL-13 blocker to mice already primed for an asthma attack. When the researchers exposed the mice to an allergen, the IL-13 blocker prevented airway tightening and the increase in mucus production typical of asthma. Conversely, giving IL-13 to mice not primed for an attack caused airway tightening and an increase in eosinophils, a kind of inflammatory cell prevalent in asthmatic lungs but scarce in healthy tissue.

In independent work, Gabriele Grünig and David Corry of the University of California, San Francisco, and their colleagues came up with similar results. The team applied either an inactive control protein or a drop of IL-13 blocker to the nasal passages of a different strain of mice, then exposed the animals to an asthma-inducing protein. The mice that received the IL-13 blocker had almost no airway tightening. They also had roughly one-third of the eosinophils and only half of the mucus-producing goblet cells seen in mice that received only the allergen. The team also tested IL-13 and IL-4 head-to-head by applying them directly to the mice's nasal passages. The mice that received IL-13 appeared to have worse symptoms. “While IL-4 plays a role,” Corry says, “IL-13 may be more potent.”

Taking your breath away.

A normal lung is clear (left), but the molecule IL-13 may trigger mucus production and airway tightening, as shown in a patient who died of an asthma attack (right).


The papers present “very convincing evidence that IL-13 has a role in these mouse models,” says immunologist Paula Jardieu of Genentech in South San Francisco. But few asthma researchers, including Jardieu, are ready to discount IL-4. They note that IL-4 prompts immature T cells to develop into a type of cell called TH2 (for T helper 2), which are a hallmark of asthma and allergic diseases. These cells produce IL-13, more IL-4, and several other asthma-inducing molecules. “Maybe IL-13 does more on a quantitative basis, but you don't get TH2 cells in absence of IL-4,” says immunologist Lanny Rosenwasser of National Jewish Medical and Research Center in Denver. And without TH2 cells, he says, there is no asthma.

Several researchers say that perhaps a more promising drug target than either cytokine is the portion of the receptor molecule on immune system cells that is shared by both IL-4 and IL-13. Indeed, in Corry's experiments, a strain of mice genetically engineered to lack this part of the receptor did not develop signs of asthma when they were given either cytokine. Several companies are already seeking an effective way to block the receptor's signaling. “[The cytokines] won't give you asthma without that receptor,” Corry says. “That kind of bottleneck is the perfect target for designing new therapies.”

Related Content

Navigate This Article